Therapeutic antibody against phosphorylcholine preserves coronary function and attenuates vascular F-18-FDG uptake in atherosclerotic mice

Stahle, M.; Silvola, J.M.U.; Hellberg, S.; Vries, M. de; Quax, P.H.A.; Kroon, J.; ... ; Saraste, A. (2020)

Article / Letter to editor

This study showed that treatment with a therapeutic monoclonal immunoglobutin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-18-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

• atherosclerosis
• coronary flow reserve
• inflammation
• F-18-fluorodeozyglucose positron emission tomography
• phosphorylcholine

• All authors: Stahle, M.; Silvola, J.M.U.; Hellberg, S.; Vries, M. de; Quax, P.H.A.; Kroon, J.; Rinne, P.; Jong, A. de; Liljenback, H.; Savisto, N.; Wickman, A.; Stroes, E.S.G.; Yla-Herttuala, S.; Saukko, P.; Abrahamsson, T.; Pettersson, K.; Knuuti, J.; Roivainen, A.; Saraste, A.
• Date: 2020-04-01
• Journal: JACC: Basic to Translational Science
• Volume: 5
• Issue: 4
• Pages: 360 - 373
• DOI: doi:10.1016/j.jacbts.2020.01.008